- Home
- MAIA vs ANVS Comparison
MAIA vs ANVS Comparison
Compare MAIA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ANVS
- Stock Information
- Founded
- MAIA 2018
- ANVS 2008
- Country
- MAIA United States
- ANVS United States
- Employees
- MAIA N/A
- ANVS 6
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- ANVS Health Care
- Exchange
- MAIA Nasdaq
- ANVS Nasdaq
- Market Cap
- MAIA 46.7M
- ANVS 44.6M
- IPO Year
- MAIA 2022
- ANVS 2020
- Fundamental
- Price
- MAIA $1.90
- ANVS $2.38
- Analyst Decision
- MAIA
- ANVS Strong Buy
- Analyst Count
- MAIA 0
- ANVS 5
- Target Price
- MAIA N/A
- ANVS $30.25
- AVG Volume (30 Days)
- MAIA 540.7K
- ANVS 607.7K
- Earning Date
- MAIA 08-08-2025
- ANVS 08-14-2025
- Dividend Yield
- MAIA N/A
- ANVS N/A
- EPS Growth
- MAIA N/A
- ANVS N/A
- EPS
- MAIA N/A
- ANVS N/A
- Revenue
- MAIA N/A
- ANVS N/A
- Revenue This Year
- MAIA N/A
- ANVS N/A
- Revenue Next Year
- MAIA N/A
- ANVS N/A
- P/E Ratio
- MAIA N/A
- ANVS N/A
- Revenue Growth
- MAIA N/A
- ANVS N/A
- 52 Week Low
- MAIA $1.40
- ANVS $1.11
- 52 Week High
- MAIA $4.24
- ANVS $17.88
- Technical
- Relative Strength Index (RSI)
- MAIA 56.86
- ANVS 48.74
- Support Level
- MAIA $1.60
- ANVS $2.05
- Resistance Level
- MAIA $2.03
- ANVS $3.18
- Average True Range (ATR)
- MAIA 0.12
- ANVS 0.27
- MACD
- MAIA 0.02
- ANVS -0.09
- Stochastic Oscillator
- MAIA 69.77
- ANVS 29.20
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.